Clinical Trial Update: Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating icotinib as adjuvant therapy for stage IIA-IIIA EGFR-mutant adenocarcinoma of the lung (non-small cell lung cancer) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED